Massachusetts’ largest life science employer has put greater than 630,000 sq. ft of workplace area on the sublease market as a part of efforts to consolidate the Japanese firm’s U.S. company hub at a brand new Cambridge growth scheduled to open later this yr.
A Takeda spokesperson instructed Fierce Biotech that it was on observe to open its new R&D facility being developed by BioMed Realty in Kendall Sq. later this yr, which it introduced in 2022. Positioned at 585 Kendall St., it can occupy 600,000 sq. ft of lab and workplace area and embrace a 30,000-square-foot performing arts middle with a 400-seat efficiency area.
The downsize will convey the corporate’s presence to 1.43 million sq. ft of area in Cambridge throughout 4 buildings, a drop from its earlier 1.56 million-square-foot footprint throughout seven buildings.
“Our technique has been to convey collectively Takeda’s world R&D middle and different key operations right into a One Cambridge campus, increasing our presence in Kendall Sq.,” a Takeda spokesperson instructed Fierce. “The brand new 585 Kendall facility can be a state‑of‑the‑artwork area that brings science and know-how collectively to boost collaboration.”
The Massive Pharma is seeking to sublease properties at 300 Massachusetts Ave., 35 Landsdowne St. and 40 Landsdowne St. for a complete of 630,153 sq. ft.
Takeda can be advertising and marketing round 125,000 sq. ft of area at 75 Binney St. in Cambridge that grew to become accessible after a subtenant vacated the property. “This availability is unrelated to Takeda’s One Cambridge Campus and represents true extra capability,” a Takeda spokesperson mentioned.
Along with the brand new facility, Takeda not too long ago renewed a portion of its long-term lease at 125 Binney St. in Cambridge with Alexandria Equities till 2040.
The consolidation follows Takeda’s layoff of 137 workers that coincided with the closure of its cell remedy facility in October. The corporate introduced that it was looking for a companion to take over Takeda’s cell remedy platform, and Fierce Biotech reported the closure of the 24,000-square-foot R&D cell remedy manufacturing facility that had opened in 2020.
In response to questions on actual property reshuffling, a Takeda spokesperson shared the corporate could be repurposing the Lexington, Massachusetts, cell remedy facility to help different Takeda therapeutic applications.
The cell remedy facility closure displays Takeda’s refinement to 3 modalities: small molecules, biologics and antibody-drug conjugates. The abandonment of cell remedy candidates meant forsaking GammaDelta Therapeutics, which Takeda purchased in 2021 and finally led to an anticipated impairment lack of about $394 million in 2025.
The Takeda consolidation follows layoffs earlier this month from fellow Massachusetts life science firm Thermo Fisher Scientific, which continued its run of cuts tied to the closure of its Franklin, Massachusetts, website.
A state Employee Adjustment and Retraining Notification Act discover listed 103 affected roles, however a Thermo Fisher firm spokesperson instructed Fierce that the max variety of layoffs could be 80 staffers. The spokesperson mentioned the remaining 120 folks on the 200-person website could be relocated to different services within the state.
Takeda’s actual property downsize will add to the area’s rising workplace sublease market. A January 2026 CBRE report on the Boston space life science actual property market discovered that emptiness climbed to an all-time excessive of 28% within the life science sector within the fourth quarter of 2025 and that new development had slowed as effectively.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s developments at present: learn extra, subscribe to our publication, and turn out to be a part of the NextTech neighborhood at NextTech-news.com
